Abstract CT016: Clinical activity of single-agent ZN-c3, an oral WEE1 inhibitor, in a phase 1 dose-escalation trial in patients with advanced solid tumorsAnthony W. Tolcher, D. Voliotis, Lukas Makris et al.|Cancer Research|2021Cited by 24